Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection (original) (raw)
Campana D, Coustan-Smith E . Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999; 38: 139–152. ArticleCAS Google Scholar
Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ . Minimal residual disease in leukaemia patients. Lancet Oncol 2001; 2: 409–417. ArticleCAS Google Scholar
van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731–1738. ArticleCAS Google Scholar
Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer: Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339: 591–598. ArticleCAS Google Scholar
Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351: 550–554. ArticleCAS Google Scholar
Dworzak MN, Froschl G, Printz D, Mann G, Potschger U, Muhlegger N et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99: 1952–1958. ArticleCAS Google Scholar
Björklund E, Mazur J, Soderhall S, Porwit-MacDonald A . Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia. Leukemia 2003; 17: 138–148. Article Google Scholar
Vidriales MB, Perez JJ, Lopez-Berges MC, Gutierrez N, Ciudad J, Lucio P et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood 2003; 101: 4695–4700. ArticleCAS Google Scholar
San Miguel JF, Ciudad J, Vidriales MB, Orfao A, Lucio P, Porwit-Mac Donald A et al. Immunophenotypical detection of minimal residual disease in acute leukemia. Crit Rev Oncol/Hematol 1999; 32: 175–185. ArticleCAS Google Scholar
Campana D . Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003; 121: 823–828. Article Google Scholar
Borella L, Casper JT, Lauer SJ . Shifts in expression of cell membrane phenotypes in childhood lymphoid malignancies at relapse. Blood 1979; 54: 64–71. CASPubMed Google Scholar
Greaves M, Paxton A, Janossy G, Pain C, Johnson S, Lister TA . Acute lymphoblastic leukaemia associated antigen. III Alterations in expression during treatment and in relapse. Leuk Res 1980; 4: 1–14. ArticleCAS Google Scholar
Lauer S, Piaskowski V, Camitta B, Casper J . Bone marrow and extramedullary variations of cell membrane antigen expression in childhood lymphoid neoplasias at relapse. Leuk Res 1982; 6: 769–774. ArticleCAS Google Scholar
Pui CH, Raimondi SC, Head DR, Schell MJ, Rivera GK, Mirro JJ et al. Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood 1991; 78: 1327–1337. CASPubMed Google Scholar
Raghavachar A, Thiel E, Bartram CR . Analyses of phenotype and genotype in acute lymphoblastic leukemias at first presentation and in relapse. Blood 1987; 70: 1079–1083. CASPubMed Google Scholar
Abshire TC, Buchanan GR, Jackson JF, Shuster JJ, Brock B, Head D et al. Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukaemia at diagnosis and relapse: a Pediatric Oncology Group study. Leukemia 1992; 6: 357–362. CASPubMed Google Scholar
van Wering ER, Beishuizen A, Roeffen ET, van der Linden-Schrever BE, Verhoeven MA, Hahlen K et al. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. Leukemia 1995; 9: 1523–1533. CASPubMed Google Scholar
Baer MR, Stewart CC, Dodge RK, Leget G, Sule N, Mrozek K et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001; 97: 3574–3580. ArticleCAS Google Scholar
Coustan-Smith E, Sancho J, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002; 100: 2399–2402. ArticleCAS Google Scholar
Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnik HR, et al., The FAB cooperative group. The morphological classification of acute lymphoblastic leukemia: concordance among observers and clinical correlation. Br J Haematol 1981; 47: 553–561. Article Google Scholar
Jennings CD, Foon A . Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood 1997; 90: 2863–2892. CASPubMed Google Scholar
Basso G, Buldini B, De Zen L, Orfao A . New methodologic approaches for immunophenotyping acute leukemias. Haematologica 2001; 86: 675–692. CASPubMed Google Scholar
Pongers-Willemse MJ, Seriu T, Stolz F, d’Aniello E, Gameiro P, Pisa P et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 110–118. ArticleCAS Google Scholar
Szczepanski T, Langerak AW, Wolvers-Tettero IL, Ossenkoppele GJ, Verhoef G, Stul M et al. Immunoglobulin and T cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: implications for selection of PCR targets for detection of minimal residual disease. Leukemia 1998; 12: 1081–1088. ArticleCAS Google Scholar
van der Velden VHJ, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJM . Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013–1034. ArticleCAS Google Scholar
Verhagen O, Willemse M, Breunis W, Wijkhuis A, Jacobs D, Joosten S et al. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 2000; 14: 1426–1435. ArticleCAS Google Scholar
Veltroni O, De Zen O, Sanzari MC, Maglia O, Dworzak MN, Ratei R, et al., on behalf of the I-BFM-ALL-FCM-MRD-Study Group. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia. Haematologica 2003; 11: 1245–1252. Google Scholar
Dworzak MN, Panzer-Grumayer ER . Flow cytometric detection of minimal residual disease in acute lymphoblastic leukemia. Leuk Lymphoma 2003; 44: 1445–1455. Article Google Scholar
Chorvath B, Sedlak J, Duraj J, Pleskova I, Dubovsky P, Augustinova Doxiadis I et al. Modulation of CALLA (CD10) antigen on cultured ALL (REH) cells: effect of various modulators. Neoplasma 1990; 37: 609–618. CASPubMed Google Scholar
Al-Katib A, Mohammad RM, Khan K, Dan ME, Pettit GR, Sensenbrenner LL . Bryostatin 1-induced modulation of the acute lymphoblastic leukaemia cell line Reh. J Immunother 1993; 14: 33–42. ArticleCAS Google Scholar
Stahnke K, Eckhoff S, Mohr A, Meyer LH, Debatin KM . Apoptosis induction in peripheral leukemia cells by remission induction treatment in vivo: selective depletion and apoptosis in a CD34+ subpopulation of leukemia cells. Leukemia 2003; 17: 2130–2139. ArticleCAS Google Scholar